DACTOLISIB
Total Payments
$19,016
Transactions
2
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $1,875 | 1 | 0 |
| 2017 | $17,141 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $19,016 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| PHASE IB DOSE FINDING STUDY OF ABIRATERONE ACETATE PLUS BEZ235 OR BKM120 IN PATIENTS WITH CASTRATION RESISTANT PROSTATE CANCER | Novartis Pharmaceuticals Corporation | $17,141 | 0 |
| RANDOMIZED PHASE II STUDY OF BEZ235 VS PLACEBO IN ADVANCED PANCREATIC NEUROENDOCRINE TUMORS | Novartis Pharmaceuticals Corporation | $1,875 | 0 |
Top Doctors Receiving Payments for DACTOLISIB
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Los Angeles, CA | $19,016 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $19,016
- Total Doctors 0
- Transactions 2
About DACTOLISIB
DACTOLISIB is a drug associated with $19,016 in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2018. In 2018, $1,875 was paid across 1 transactions to 0 doctors.
The most common payment nature for DACTOLISIB is "Unspecified" ($19,016, 100.0% of total).
DACTOLISIB is associated with 2 research studies, including "PHASE IB DOSE FINDING STUDY OF ABIRATERONE ACETATE PLUS BEZ235 OR BKM120 IN PATIENTS WITH CASTRATION RESISTANT PROSTATE CANCER" ($17,141).